GNE-617

CAS No. 1362154-70-8

GNE-617( GNE-617 | GNE 617 | GNE617 )

Catalog No. M17972 CAS No. 1362154-70-8

GNE-617, a specific NAMPT inhibitor(IC50=5 nM), shows potency in xenograft models of cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 74 In Stock
2MG 46 In Stock
5MG 73 In Stock
10MG 120 In Stock
25MG 219 In Stock
50MG 343 In Stock
100MG 511 In Stock
200MG Get Quote In Stock
500MG 1107 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    GNE-617
  • Note
    Research use only, not for human use.
  • Brief Description
    GNE-617, a specific NAMPT inhibitor(IC50=5 nM), shows potency in xenograft models of cancer.
  • Description
    GNE-617 is a potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitor with IC50 value of 5nM. Prolonged inhibition of nicotinamide phosphoribosyltransferase (NAMPT) is a strategy for targeting cancer metabolism.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    GNE-617 | GNE 617 | GNE617
  • Pathway
    MAPK/ERK Signaling
  • Target
    JNK
  • Recptor
    NAMPT
  • Research Area
    Metabolic Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    1362154-70-8
  • Formula Weight
    427.43
  • Molecular Formula
    C21H15F2N3O3S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : ≥ 42.85 mg/mL; 100.25 mM
  • SMILES
    C1=CC(=CC=C1CNC(=O)C2=CN3C=CN=C3C=C2)S(=O)(=O)C4=CC(=CC(=C4)F)F
  • Chemical Name
    N-(4-((3,5-difluorophenyl)sulfonyl)benzyl)imidazo[1,2-a]pyridine-6-carboxamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Shames DS, et al. Loss of NAPRT1 Expression by Tumor-specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors. Clin Cancer Res. 2013 Dec 15;19(24):6912-23.
molnova catalog
related products
  • SR-3306

    SR-3306 is a highly selective, brain penetrant, potent inhibitor of JNK with IC50 of 67, 283 and 159 nM for JNK1, JNK2 and JNK3.

  • GSK2879552 2HCl

    GSK2879552 is an orally available, irreversible inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity.

  • CC-90001

    CC-90001 is an orally administered c-Jun N-terminal kinase (JNK) inhibitor with bias for JNK1 over JNK2.